Benign Prostatic Hypertrophy

News Benign Prostatic Hypertrophy

• AmVac AG Granted a European Patent for ProstaVac

  European patent EP 1272216B1 with the title "Vaccine consisting of lactobacilli for the treatment of inflammation of the prostate and benign prostatic hyperplasia" was granted by the European Patent Office on9.6.2010. AmVac AG holds a licence for the above patent. Granting of the patent is a major more

• Protox announces positive Phase 2b BPH results

  Protox Therapeutics Inc. announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH). The study achieved its primary clinical endpoint of a statistically significa more

• Protox completes enrollment of Phase 2b BPH trial

  Protox Therapeutics Inc. announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH). TRIUMPH is the third BPH clinical trial of PRX302 c more

Publications Benign Prostatic Hypertrophy

• Phosphodiesterase inhibitors in clinical urology

  To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic hyperplasia and symptoms of female sexual dysfunction (including arousal and orgasmic disorders), can more

• Electroacupuncture for Moderate and Severe Benign Prostatic Hyperplasia: A Randomized Controlled Trial

  by Yang Wang, Baoyan Liu, Jinna Yu, Jiani Wu, Jing Wang, Zhishun Liu Purpose To evaluate the effects of electroacupuncture (EA) on the International Prostate Symptom Score (IPSS), postvoid residual urine (PVR), and maximum urinary flow rate (Qmax), and explore the difference between EA at acupoin more

• Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist [Medical Sciences]

  Gastrin releasing-peptide (GRP) is a potent growth factor in many malignancies. Benign prostatic hyperplasia (BPH) is a progressive age-related proliferation of glandular and stromal tissues; various growth factors and inflammatory processes are involved in its pathogenesis. We have demonstrated tha more

Market studies Benign Prostatic Hypertrophy

• Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth

  GBI Research, the leading business intelligence provider, has released its latest research “Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth”. The report provides in-depth analysis of drivers and barriers that impact the global men’s h more

• Sophiris Bio, Inc. (SHS) - Financial and Strategic SWOT Analysis Review

  Sophiris Bio, Inc. (SHS) - Financial and Strategic SWOT Analysis Review Summary Sophiris Bio, Inc. (Sophiris), formerly Protox Therapeutics Inc., is a biopharmaceutical company. It focuses on the research, development and commercialization of products for the treatment of urological diseases, such more

• Benign Prostatic Hyperplasia – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Benign Prostatic Hyperplasia - Pipeline Review, H2 2012', provides an overview of the Benign Prostatic Hyperplasia therapeutic pipeline. This report provides information on the therapeutic development for Benign Prostatic Hyperplasia, complete with latest upd more

Websites Benign Prostatic Hypertrophy